The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.
Original Article: Samsung Bioepis-Merck biosimilar to Roche's Herceptin wins FDA nod